Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461908 | 0.94 | CYP19A1 (0.63) | CYP19A1CYP11B2CYP3A4KCNA5CYP11B1 | |
| SCHEMBL4469599 | 0.87 | CYP19A1 (0.51) | CYP19A1CYP11B2CYP3A4KCNA5CYP11B1 | |
| SCHEMBL4462079 | 0.87 | CYP19A1 (0.51) | CYP19A1CYP11B2CYP3A4KCNA5CYP11B1 | |
| SCHEMBL4472869 | 0.86 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP3A4KCNA5 | |
| SCHEMBL4459003 | 0.86 | CYP19A1 (0.49) | CYP19A1CYP11B2KCNA5CYP11B1CYP17A1 | |
| SCHEMBL14435411 | 0.84 | CFTR (0.50) | CYP19A1CYP3A4KCNA5CYP17A1CFTR | |
| SCHEMBL4460426 | 0.84 | CYP19A1 (0.48) | CYP19A1CYP11B2KCNA5NPY5R | |
| SCHEMBL4466454 | 0.83 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP3A4KCNA5 | |
| SCHEMBL4458259 | 0.82 | CFTR (0.55) | CYP19A1KCNA5CFTRSLC6A2SLC6A4 | |
| SCHEMBL4461911 | 0.82 | CYP19A1 (0.46) | CYP19A1CYP11B2CYP3A4KCNA5SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CYP19A1 4359/4885CYP11B2 1911/4885CYP3A4 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.